MRVI vs TMO: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

TMO is the larger of the two ($249.73B market cap): the incumbent the market prices for continued execution (24.26x forward earnings, beta 0.85). MRVI is the smaller challenger ($1.83B), still expected to post a loss next year: more room to run, but more to prove. If the story you believe is MRVI's (TriLink base mRNA demand outside COVID), MRVI is the more direct way to own it; if it is TMO's (Bioprocessing and Biologic Drug Manufacturing Tailwind), TMO is.

MRVI vs TMO: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricMRVITMOWhat it tells you
Market cap$1.83B$249.73BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-93.0324.26Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta0.630.85Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range64% of range82% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book5.374.56How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how MRVI and TMO affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MRVI and TMO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MRVI and TMO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Maravai LifeSciences (MRVI) do?

Maravai LifeSciences is a San Diego life sciences tools company that GTCR controls. It runs two businesses. The larger is TriLink BioTechnologies, which makes the nucleic acid building blocks behind mRNA medicines: CleanCap capping reagents, modified nucleotides, enzymes, DNA templates and custom mRNA, sold for research and in GMP grade for clinical and commercial production. The second is Cygnus Technologies. It sells host cell protein (HCP) detection kits, ELISA assays and related services, which biologics manufacturers use to show regulators that impurities have been removed from their drugs. In 2021 and 2022, CleanCap orders tied to COVID vaccines pushed revenue close to $900M. When those orders went away, revenue fell to about $186M in 2025, along with large losses, goodwill writedowns and layoffs.

Full MRVI guide

What does Thermo Fisher Scientific (TMO) do?

Thermo Fisher Scientific, headquartered in Waltham, Massachusetts, is a global provider of scientific instruments, consumables, reagents, and services used across pharmaceutical and biotech drug development, clinical diagnostics, academic research, and environmental and industrial testing. The company operates through four reportable segments: Life Sciences Solutions (reagents, proteins, and consumables for research and bioproduction), Analytical Instruments (mass spectrometers, chromatography systems, electron microscopes, and laboratory equipment), Specialty Diagnostics (clinical diagnostic kits and transplant diagnostics), and Laboratory Products and Biopharma Services (supply-chain distribution, contract research through PPD, and contract drug manufacturing through Patheon). Revenue is generated through instrument sales, high-margin consumables and reagents that customers repurchase continuously, long-term service contracts, and growing contract development and manufacturing (CDMO) fees; consumables and services collectively account for a majority of annual sales and provide durable recurring revenue.

Full TMO guide

MRVI vs TMO: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • MRVI drivers: TriLink base mRNA demand outside COVID; Margin repair and operating leverage.
  • TMO drivers: Bioprocessing and Biologic Drug Manufacturing Tailwind; Recurring Consumables and Reagents Engine.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Valuation is the first risk. For TMO, the most significant near-term risk is a contraction in research funding from government agencies (including NIH) and from biotech companies whose access to capital markets has historically been cyclical; when funding tightens, customers delay instrument purchases and reduce consumable orders, pressuring organic revenue growth.

MRVI or TMO: which should you pick?

With growth, valuation and volatility this close (or not yet reported for one side), the drivers above are what separate MRVI from TMO. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the MRVI and TMO guides.

MRVI vs TMO: the full fundamentals

MRVI. The market cap above counts all ~260M Class A shares and exchangeable Class B units at about $7.03, which matches the figure Yahoo Finance shows. Adding ~$226M of debt and subtracting ~$73M of cash gives an enterprise value near $2.0B, about 9x trailing sales and roughly 48x the midpoint of the raised adjusted EBITDA guidance, still well above many slower-growth life sciences tools peers. GAAP results are still loss-making (a ~$24.0M Q3 net loss), so investors are valuing adjusted EBITDA and its direction. Seven analysts tracked by Yahoo Finance carry a mean target near $9.64.

TMO. Thermo Fisher trades at roughly 24 times forward earnings and ~36 times trailing GAAP earnings, which include heavy acquisition amortization, after a third quarter that beat on EPS for the fourth time running. Analysts expect 2026 adjusted EPS of ~$25.28 on ~$48.0 billion of revenue and ~$27.79 on ~$50.5 billion in 2027, roughly 10% growth each year, and the ~$757 mean target from 25 analysts sits about 12% above the November 20 price. Trailing free cash flow of ~$6.4 billion still gives the company flexibility for repurchases, dividends and acquisitions.

Headline figures (approximate, November 2026): MRVI shows revenue (ttm) ~$213M (Q3 2026 +10% YoY), 2026 revenue guidance ~$212M to $216M (raised from $205M to $215M), 2026 adj. ebitda guidance ~$40M to $42M (raised from $33M to $35M), q3 2026 adj. eps -$0.03 vs ~-$0.06 consensus; TMO shows revenue (ttm) ~$47.4 billion; full year 2025 ~$44.6 billion, q3 2026 revenue ~$12.14 billion, up ~9% year over year, q3 2026 adjusted eps ~$6.68 vs ~$6.40 expected, margins (ttm) Gross ~41%, GAAP operating ~19%, net ~15%.

The bottom line: MRVI vs TMO

MRVI and TMO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined MRVI and TMO exposure against your real portfolio. It is not an investment adviser.

Wondering how MRVI or TMO fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Maravai LifeSciences

Ask Walnut's AI anything about MRVI and see how it fits what you own.

FAQ

What is the difference between MRVI and TMO?

+

Maravai LifeSciences is a San Diego life sciences tools company that GTCR controls. Thermo Fisher Scientific, headquartered in Waltham, Massachusetts, is a global provider of scientific instruments, consumables, reagents, and services used across pharmaceutical and biotech drug development, clinical diagnostics, academic research, and environmental and industrial testing. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is MRVI or TMO the better stock?

+

Neither is universally better. TMO is the larger incumbent; MRVI is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, MRVI or TMO?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both MRVI and TMO?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of MRVI vs TMO?

+

MRVI: Valuation is the first risk. At about $7.03, MRVI trades near 9x trailing sales of ~$213M and more than 40x the midpoint of the raised 2026 adjusted EBITDA guidance, which leaves little room for a weak quarter; consensus also has 2027 revenue only about 5% above 2026 guidance. Revenue is concentrated: Pfizer accounted for ~12% of first-half revenue, and a single vaccine customer accounted for ~18% of receivables at mid-year. Management has said it does not expect more high-volume COVID orders in 2026, and Q2 COVID CleanCap revenue was zero, so the year-over-year comparison gets harder. Cash fell from ~$217M at year-end 2025 to ~$70M at June 30, 2026, mostly because the company used cash to repay debt, leaving a $150M term loan due 2032; Yahoo Finance shows ~$73M of cash and ~$226M of total debt after Q3. Wider mRNA sentiment, including US policy pullbacks on mRNA vaccine funding, can hit research budgets. Competition from Thermo Fisher, Danaher's Aldevron and low-cost Chinese suppliers could pressure CleanCap pricing as patents age. GTCR controls the majority of voting power, so outside shareholders have limited influence, and future GTCR sales could add supply. The stock moves sharply in both directions: it fell about 22% over the three months to November 20, 2026 even as guidance rose. TMO: The most significant near-term risk is a contraction in research funding from government agencies (including NIH) and from biotech companies whose access to capital markets has historically been cyclical; when funding tightens, customers delay instrument purchases and reduce consumable orders, pressuring organic revenue growth. Thermo Fisher's active acquisition strategy carries integration and leverage risk, particularly after committing approximately $13 billion to mergers and acquisitions in 2025 alone; total debt stood near ~$41.4 billion against ~$6.1 billion of cash on the September 2026 balance sheet, and a large deal that underperforms expectations could weigh on earnings and the balance sheet simultaneously. Geopolitical friction, particularly regarding China, creates both a demand risk (softer orders from Chinese academic and industrial customers) and a supply chain risk, while tariff policy changes can disrupt cost structures. Finally, valuation risk remains: the stock trades near ~36 times trailing GAAP earnings and ~24 times forward estimates, so a slip in growth from the third quarter's ~9% pace would test a multiple that has already expanded this year.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell MRVI or TMO; figures are approximate and dated (as of November 2026). Verify current data before investing.